BTQ2302

BTQ2302 is a fixed-dose combination ophthalmic drug candidate comprising timolol and latanoprost, formulated using the proprietary EyeSol technology. This water-free formulation is being developed for the treatment of elevated intraocular pressure, primarily in conditions such as glaucoma and ocular hypertension. The EyeSol platform enables improved ocular tolerability by eliminating preservatives and water-based excipients, potentially reducing irritation and enhancing drug delivery to ocular tissues. Timolol is a non-selective beta-adrenergic antagonist that lowers intraocular pressure by decreasing aqueous humor production, while latanoprost is a prostaglandin F2α analog that increases uveoscleral outflow of aqueous humor[2][4].